Filters

Pp-228 manufacturers

Filters

None products found

pp-228

Tablets

Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Plaque Psoriasis & Systemic Lupus Erythematosus (SLE) / Clinical stage: Phase 3 / Modality: Small molecule tyrosine kinase-2 (TYK2) inhibitor / Mechanism & Target: Selective oral TYK2 inhibitor / Route & form: Oral / Differentiation: Leading skin clearance in psoriasis (65% PASI90 at Wk24)
Manufacturer #39435
Clinical-stage biopharmaceutical company focused on immune-mediated inflammatory diseases. Develops selective oral small molecules targeting autoimmune signaling pathways. Advances precision therapies through late-stage global Phase 3 clinical programs.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.